WNBA Modernizes Policy: Marijuana No Longer a Banned Substance

The Women’s National Basketball Association has removed marijuana from its list of banned substances through a newly approved collective bargaining agreement with the players’ union. The update reflects a broader shift in how the league handles cannabis, moving away from automatic penalties toward clearer guidelines on impairment and player conduct.

Under the deal, routine testing for marijuana will no longer take place in most situations. Testing can still occur if a player enters the league’s substance program, shows signs of being impaired while working with the team, or raises concerns about dependency. Players who enter treatment are expected to complete it as directed. Those who fall short face daily fines starting at $300, with more serious or repeated issues leading to higher fines or suspensions of multiple games.

The agreement also adds new substances to the prohibited list. Several psychedelics, including psilocybin, DMT, and ibogaine, are now banned. Synthetic forms of cannabinoids, such as Delta-8 THC and related compounds, have been added as well. These additions show the league is drawing firmer lines around certain products even as it relaxes rules on traditional marijuana.

Players now have limited ways to participate in cannabis-related businesses. They can hold a passive ownership stake below 50 percent in marijuana companies, as long as they stay out of management, voting, or day-to-day operations. Any investment must follow state and federal laws and cannot involve companies that deal in banned substances.

Rules for CBD products are more open. Players may actively endorse and promote CBD brands and face fewer barriers to ownership. However, products tied to marijuana companies or those that might confuse the public require prior approval from the league and union. Any deal that crosses into restricted territory must be ended.

This policy change brings the WNBA closer to the approach already used by the NBA, which stopped routine marijuana testing several years ago. It recognizes that many athletes turn to cannabis for recovery, pain relief, and sleep, and that off-duty use under state law does not automatically harm performance or team standards. At the same time, the league keeps authority to act when impairment or treatment issues arise.

The updates give players more personal freedom while setting practical boundaries. Ownership stakes and endorsement deals create new opportunities, but the approval process and ownership limits are designed to avoid conflicts or public confusion. The focus remains on keeping games fair and players accountable for their on-court responsibilities.

League and union leaders have described the full agreement as a significant step forward for the sport. By updating these rules, the WNBA is responding to changing views on cannabis across professional athletics and society. The policy balances greater autonomy for players with continued protections around safety, treatment, and professional standards.

In practice, players will face less risk of discipline for personal marijuana use outside of work. They will still need to stay clear of impairment during team activities and follow treatment plans when required. The new restrictions on psychedelics and synthetic cannabinoids send a clear signal that not every cannabis-related product receives the same treatment.

Overall, the changes modernize the league’s stance without removing all oversight. They give athletes room to make decisions about their bodies and side interests while maintaining the league’s responsibility to protect the game and its standards. The WNBA and its players’ union will watch how the rules work in real conditions and can adjust as needed in the years ahead.